Advertisement
The Body: The Complete HIV/AIDS Resource
Sign up for free e-mail updates!The Body en Espanol
  • E-mail E-Mail
  • Printer Friendly Printable Single-Page
  • Glossary Glossary
  • PDF PDF
  • Bookmark and Share Share
Seattle Treatment Education Project

News Flash!! Once-a-Day Triple NRTI Warning

October 27, 2003


This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Gilead Sciences, Inc., the manufacturer of the anti-HIV medication Tenofovir (Viread) today issued a "Dear Health Care Professional" letter (click here to view) describing high rates of virologic failure in patients treated with a "once-a-day" triple NRTI regimen that contains: Didanosine (ddI, Videx EC), Lamivudine (3TC, Epivir), and Tenofovir (Viread). This letter is somewhat technical and difficult to understand. Please call Roberto González at 206-957-1659 or 1-888-399-7837 if you would like further explanation.



This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.


This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
  • E-mail E-Mail
  • Printer Friendly Printable Single-Page
  • Glossary Glossary
  • PDF PDF
  • Bookmark and Share Share

See Also
More on HIV Medications

 

Advertisement